Document Detail


Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents.
MedLine Citation:
PMID:  23277264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Clinical antipsychotic trials of intervention effectiveness showed that atypical antipsychotics (AAPs) were associated with significant weight gain and glucose intolerance. A few trials have shown topiramate to reduce weight gain in patients receiving AAPs, although this benefit has not been present in all trials.
OBJECTIVE: This study aimed to determine topiramate therapy's impact on weight gain in patients receiving AAPs.
DATA SOURCE: A systematic literature search of MEDLINE (1948 to July 8, 2011) and Cochrane CENTRAL (4th Quarter 2011) was conducted.
STUDY SELECTION: Eight trials (n = 336 participants) met our inclusion criteria: randomized controlled trial, evaluated topiramate in patients taking AAPs, and reported weight change during the treatment course.
DATA EXTRACTION: Two investigators (S.M. and C.I.C.) used a standardized data abstraction tool to independently collect data, with disagreement resolved through discussion. The difference between the mean weight in the topiramate and control groups was calculated as the weighted mean difference with accompanying 95% confidence interval. A random effect model was used for all analyses.
DATA SYNTHESIS: Upon meta-analysis, we found that patients receiving topiramate lost weight or had attenuated weight gain compared to control patients (weighted mean difference, -2.83 kg; 95% confidence interval, -4.62 to -1.03).
CONCLUSIONS: Our meta-analysis shows that using topiramate can prevent or reduce weight gain associated with AAPs.
Authors:
Shamail Mahmood; Ian Booker; Judy Huang; Craig I Coleman
Related Documents :
3961834 - Screening for depression in stroke patients: the reliability and validity of the center...
489744 - Lewinsohn's behavioral measures of social skill: their stability and relationship to mo...
11668774 - Socioeconomic status and depressive syndrome: the role of inter- and intra-generational...
18709704 - Recognition of depression among women presenting with menopausal symptoms.
15352644 - Treatment of opiate-related sedation: utility of the cholinesterase inhibitors.
9746864 - Intra-articular corticosteroids in the treatment of juvenile rheumatoid arthritis.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  33     ISSN:  1533-712X     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-06-12     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  90-4     Citation Subset:  IM    
Affiliation:
Department of Preventive Medicine, Griffin Hospital, Derby, CT, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Obesity Agents / therapeutic use*
Antipsychotic Agents / adverse effects*
Fructose / analogs & derivatives*,  therapeutic use
Humans
Treatment Outcome
Weight Gain / drug effects*
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Antipsychotic Agents; 0H73WJJ391/topiramate; 30237-26-4/Fructose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Leptin Plasma Concentrations Increase During Antidepressant Treatment With Amitriptyline and Mirtaza...
Next Document:  Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in...